Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
Date:1/5/2009

SAN CARLOS, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 27th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Tuesday, January 13, 2009 at 10:00 a.m. Pacific time (1:00 p.m. Eastern time).

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 15, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugate technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

     Nektar Contacts:
     Jennifer Ruddock
     Nektar Therapeutics
     650-631-4954
     jruddock@nektar.com

     Susan Noonan
     The SAN Group
     212-966-3650
     susan@sanoonan.com

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
2. Nektar Therapeutics to Webcast R&D Day on November 12th
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
6. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
7. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
8. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
9. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
10. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
11. West Concludes Agreement with Nektar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... July 10, 2014  Kainos Capital, a firm specializing ... announced that it has acquired the Slim-Fast brand from ... business. Terms of the transaction were not disclosed. ... replacement business that markets ready-to-drink shakes, powders, bars and ... and in the United Kingdom ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... 31 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) ... NewsMakers in the Biotech Industry conference in New,York. ... Thursday, September,6, 2007 at 2:00 p.m. Eastern Time ... . The presentation will be archived for seven ...
... FREMONT, Calif., Aug. 30 ARYx Therapeutics, Inc.,announced today ... S-1 with,the Securities and Exchange Commission for a proposed ... of the shares in the proposed,offering will be sold ... will be Morgan Stanley & Co.,Incorporated acting as sole ...
... (Nasdaq: VRNM ), a leading developer of cellulosic ... specialty,enzymes, announced today that Carlos A. Riva, President and ... Cowen and Company Clean,Energy Conference. The presentation is scheduled ... 2007 and will take place at Le Parker Meridien ...
Cached Biology Technology:BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 2BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 3ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 3
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... increased risk of kidney injury related to the use ... mass of HES molecules, according to a report in ... International Anesthesia Research Society (IARS). , The "total mass ... on cultured human renal proximal tubule cells (PTCs), concludes ... of University Hospital Wrzburg, Austria. Other factorssuch as ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... of Illinois at Chicago College of Pharmacy are ... an antipsychotic medication works in adults and children ... Risperidone, a popular "atypical" antipsychotic medication, is used ... bipolar disorder. , Jeffrey Bishop, assistant professor ...
... molecular mechanism underlying the hyperactive high of cocaine. In ... interactions between two types of receiving stations in neurons ... in rats found that when the animals received cocaine, ... tends to grab onto a component of a receptor ...
... demand, Montana State University entomologists are investigating ways ... the entomologists are concluding a two-year study that ... sawfly larvae that tunnel the interior of developing ... master's graduate Godshen Pallipparambil-Robert and undergraduate Melissa Frazier ...
Cached Biology News:Studies look at how genes affect antipsychotic drug response 2Cocaine high caused by interference in neuronal receiving stations 2Rearing an army to save wheat 2Rearing an army to save wheat 3
... MBPK Antibody - Red, 20X ... MBPK antibody at 20X concentration for ... polarization assays. Quality ... 645nm FarRed fluorescence polarization assays. ...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: